Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis launched its urology business in early 2015, which includes a patented formulation to address patients suffering from interstitial cystitis.
San Diego, US
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
350 12264 El Camino Real

Imprimis Pharmaceuticals Metrics

Imprimis Pharmaceuticals Financial Metrics

Revenue (2016)

$19.9 m

Revenue growth (2015-16), %


Gross profit

$10.1 m

Gross profit margin (2016), %


Net income (2016)

($19.1 m)

Market capitalization (21-Mar-2017)

$31.7 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$8.9 m
Imprimis Pharmaceuticals's current market capitalization is $31.7 m.
Imprimis Pharmaceuticals's revenue was reported to be $19.9 m in FY, 2016 which is a 105% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$1.7 m$9.7 m$19.9 m

Revenue growth, %


Cost of goods sold

$1.1 m$5.2 m$9.8 m

Gross profit

$567.4 k$4.5 m$10.1 m

Gross profit Margin, %


Operating expense total

$10.7 m$19.3 m$26 m


($10.1 m)($14.8 m)($15.9 m)

EBIT margin, %


Interest expense

$3.8 k$1.1 m$2.8 m

Interest income

$32.4 k$1.1 m

Income tax expense

$111 k

Net Income

($10.1 m)($15.9 m)($19.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$15.6 m$8.2 m$2.7 m$8.9 m

Accounts Receivable

$81.3 k$840 k$2.9 m


$105.1 k$372.7 k$1.4 m$1.8 m

Current Assets

$15.7 m$9.1 m$5.9 m$14.8 m


$7.3 m


$331.6 k$2.5 m$2.2 m

Total Assets

$15.8 m$10.2 m$14.1 m$27.2 m

Accounts Payable

$311.9 k$786.7 k$3.4 m$3.5 m

Current Liabilities

$650.6 k$1.6 m$5.4 m$9.9 m

Additional Paid-in Capital

$46.8 m$50 m$56.4 m$83.3 m

Retained Earnings

($41.9 m)($57.8 m)($76.9 m)

Total Equity

$15.1 m$8.2 m($1.4 m)$6.4 m

Financial Leverage

1 x1.3 x-10.2 x4.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($7.6 m)($10.1 m)($15.9 m)($19.1 m)

Depreciation and Amortization

$5.7 k

Accounts Receivable

($22.9 k)($360 k)($2.1 m)


($17 k)($159.5 k)($314 k)($429 k)

Accounts Payable

($239.8 k)$345.4 k$1 m$1.5 m

Cash From Operating Activities

($4.4 m)($7.1 m)($11.1 m)($11.2 m)

Purchases of PP&E

($6.9 m)

Cash From Investing Activities

($70 k)($910.5 k)($5.1 m)($7.3 m)

Cash From Financing Activities

$10.1 m$598.1 k$10.7 m$24.7 m

Interest Paid

$3.8 k$637 k$1.4 m

Income Taxes Paid

$1.6 k$800$1 k$9 k

Imprimis Pharmaceuticals Market Value History

Imprimis Pharmaceuticals Online Presence

Imprimis Pharmaceuticals News

Imprimis Pharmaceuticals Company Life

You may also be interested in